9 March 2022 - NICE has published evidence based recommendations on the use of empagliflozin (Jardiance) for the treatment of adults with chronic heart failure with a reduced ejection fraction.

Empagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

• An angiotensin converting enzyme inhibitor or angiotensin 2 receptor blocker, with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist, or
• Sacubitril with valsartan and a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist

Read NICE final appraisal determination for empagliflozin